Related Experiment Video
Updated: May 26, 2026
Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?
1Department of Pathology, James Buchanan Brady Urological Institute, Johns Hopkins University, 402 N. Broadway Avenue, Weinberg Building suite 2242, Baltimore, MD 21231, USA. gnetto1@jhmi.edu
Abstract:
The unprecedented advances in cancer genetics and genomics are rapidly affecting the clinical management of solid tumors. Molecular diagnostics are now an integral part of routine clinical management for patients with lung, colon, and breast cancer. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms for urologic malignancies. The need for new treatment options that can improve upon the modest outcomes currently associated with muscle-invasive bladder cancer is evident, and validated prognostic molecular biomarkers that can help clinicians to identify patients in need of early, aggressive management are lacking. Robust predictive biomarkers that are able to forecast and stratify responses to emerging targeted therapies are also needed.
Insights
Molecular diagnostics are standard for many cancers but underutilized in urologic malignancies. Validated biomarkers are needed for bladder cancer to guide treatment and improve patient outcomes.
Area of Science:
- Oncology
- Genetics
- Molecular Diagnostics
Background:
- Advances in cancer genetics and genomics are transforming solid tumor management.
- Molecular diagnostics are integral to lung, colon, and breast cancer care.
- Urologic malignancies currently lack integration of molecular biomarkers in clinical management.
Purpose of the Study:
- To highlight the disparity in molecular biomarker integration between solid tumors and urologic malignancies.
- To emphasize the critical need for validated prognostic and predictive biomarkers in bladder cancer.
- To underscore the requirement for biomarkers to guide aggressive treatment and targeted therapy selection.
Main Methods:
- Review of current clinical management standards for solid tumors and urologic malignancies.
- Analysis of the impact of molecular diagnostics in oncology.
- Identification of gaps in biomarker utilization for bladder cancer.
Main Results:
- Molecular diagnostics are widely adopted for lung, colon, and breast cancers.
- Urologic cancers, particularly bladder cancer, lag significantly in biomarker integration.
- There is a lack of validated prognostic biomarkers for identifying patients needing aggressive treatment for muscle-invasive bladder cancer.
- Predictive biomarkers for stratifying response to targeted therapies are also absent.
Conclusions:
- There is a significant unmet need for molecular biomarkers in urologic oncology.
- Validated biomarkers are essential for improving outcomes in muscle-invasive bladder cancer.
- Biomarkers are crucial for personalizing treatment strategies and enhancing the efficacy of emerging therapies in urologic malignancies.
